NORCROSS, Ga., April 30 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its fourth generation automated instrument, NEO™, has been cleared for marketing in the U.S. by the Food and Drug Administration ("FDA"). NEO is a fully automated blood bank instrument designed to meet the needs of high volume laboratories.
"We believe there is a significant market opportunity for NEO and we are very excited about achieving 510(k) clearance from the FDA," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. "NEO is the most recent example of Immucor's commitment to deliver products that improve patient safety and the practice of transfusion medicine."
Immucor's innovative automation strategy provides scalable solutions to meet the needs of all blood banks, regardless of size. Immucor has continually invested in automation since 1998, most recently with NEO. Immucor's fourth generation automated instrument, NEO is designed to increase productivity, performance and flexibility of high volume laboratories. NEO delivers the market's highest type-and-screen throughput and broadest test menu as well as new STAT priority functionality for improved workflow.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "may," "will," "could", "should" and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements, and Immucor assumes no obligation to update any forward-looking statements. Immucor urges investors to consider the risks detailed in the Company's filings with the Securities and Exchange Commission.
|SOURCE Immucor, Inc.|
Copyright©2010 PR Newswire.
All rights reserved